Nanomerics Ltd. announced the successful completion of its OC134 Phase I trial - the SUNLIGHT trial. With the clinical phase competed the trial for OC134 and the MET platform has met its primary endpoints.
LONDON, UK / ACCESS Newswire / March 10, 2025 / Nanomerics Ltd., a private speciality pharmaceutical company today announced that it had completed 28 consecutive days of administration in its OC134 Phase I trial - the SUNLIGHT trial and discharged the last volunteer from the trial. The last volunteer, last visit event concludes the clinical part of the trial. Nanomerics is pleased to report that the trial met its primary endpoints. All volunteers (n=10) completed the 28-day consecutive twice daily (12 hours apart) dosing schedule with either MET eye drops or OC134 eye drops, and all volunteers completed the 56 day follow up visits, with no dropouts.
There were no treatment-related adverse events of moderate or severe severity reported during the clinical and follow-up phases of the trial and there were no treatment-related clinically significant individual changes from baseline or notable trends in safety assessments including safety bloods, vital signs, eye examination, 12 lead ECGs and urinalysis.
The topical administration of MET and OC134 eye drops on 56 consecutive occasions was well tolerated by healthy volunteers under the conditions of trial and no treatment-related items of concern were reported during the follow up visits.
Approval was granted for the OC134 and MET tolerability study by the UK Medicinal and Healthcare Products Regulatory Agency (MHRA) and the study was conducted by Quotient Sciences at its Nottingham, UK Phase I study site according to Good Clinical Practice guidelines.
OC134 is an eye drop medicine candidate indicated for the topical treatment of moderate to severe allergic conjunctivitis, a condition for which a suitable non-steroidal topical ocular treatment, does not currently exist. OC134 is also indicated for the topical treatment of dry eye disease.
OC134 is powered by Nanomerics' Molecular Envelope Technology (MET), a non-irritant ocular penetration enhancer. Nanomerics' MET is a platform ocular penetration enhancer, that has been shown in preclinical studies to increase the penetration of active pharmaceutical ingredients (APIs) into the front of the eye; increasing ocular deposition up to 18-fold, when compared to conventional formulations. In preclinical studies, Nanomerics' MET also demonstrated the delivery of APIs to the retina from eye drops. Nanomerics has a pipeline of ocular assets that may now be tested in clinical studies and ultimately launched for the benefit of patients. Nanomerics' MET is now a clinical stage ocular excipient.
Professor Andreas G. Schätzlein, Nanomerics' Chief Executive Officer said,
"Our last volunteer, last visit event concludes the clinical and follow-up parts of the SUNLIGHT trial and we can now proudly state that Nanomerics is a clinical stage company, with assets applicable to a broad range of ophthalmology markets. Our goal has always been to discover and develop efficient, well-tolerated therapies for patients in areas of large unmet medical need and we embark on this new phase in our company, confident that we can deliver on this singularly important goal."
Dr Nand Singh, Medical Director at Quotient Sciences commented,
We are pleased to state that the First-In-Human trial has been completed at our Nottingham, UK clinic for Nanomerics' OC134 Phase 1 SUNLIGHT trial. The trial met its primary endpoints, demonstrating favourable safety and tolerability profiles of MET and OC134 eye drops, administered as stated above, among healthy male and female volunteers. This excellent profile further warrants clinical trials in patient populations with moderate to severe allergic conjunctivitis, to further assess and achieve the critical proof of concept milestone for OC134.
About Nanomerics
Nanomerics Ltd is a speciality pharmaceutical company with state-of-the-art laboratories based in London, UK. Nanomerics was founded to commercialise its biocompatible polymer technologies for drug delivery and other applications. Nanomerics' proprietary technology is based on world leading know-how and scientific leadership in polymer nanotechnology. Nanomerics creates uniquely differentiated, patented pharmaceutical assets, underpinned by high quality science. For example, the company's Molecular Envelope Technology (MET) is a unique patented biocompatible polymer that delivers a step change in target tissue bioavailability. The founding scientists, Professor Dame Ijeoma F. Uchegbu and Professor Andreas G. Schätzlein developed the technology at the Universities of Strathclyde and Glasgow and, latterly at the UCL School of Pharmacy. Pharmaceutical product candidates in development include the eye drops: OC134 for the treatment of moderate to severe allergic conjunctivitis and dry eye disease, OC137 for the treatment of retinal diseases and OC135 for the treatment of glaucoma. For more information, please visit www.nanomerics.com.
For press enquiries contact:
Pedro Margarido
Head of Operations, Nanomerics Ltd.
pedro.margarido@nanomerics.com
About Quotient Sciences
Quotient Sciences is a drug development and manufacturing accelerator providing integrated programmes and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, Quotient saves precious time and money in getting drugs to patients. Everything Quotient does for its customers is driven by an unswerving belief that ideas need to become solutions, and molecules need to become cures, fast, because humanity needs novel therapeutic solutions, fast. Quotient Sciences has been recognized as a multi-year winner of the CRO Leadership Awards in 2021, 2022, and 2024 and of the CDMO Leadership Awards in 2023. For more information, visit quotientsciences.com.
For press enquiries, contact:
Erica Fearnley
Executive Director, Strategic Marketing at Quotient Sciences
erica.fearnley@quotientsciences.com
Rachael Heath
Senior PR Manager at RaMarketing & PR
rachael@ramarketingpr.com
SOURCE: Nanomerics Ltd
View the original press release on ACCESS Newswire
